{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T16:30:32Z","timestamp":1786379432762,"version":"build-2736575974"},"reference-count":55,"publisher":"Ovid Technologies (Wolters Kluwer Health)","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["JASN"],"abstract":"\n Key Points<\/jats:title>\n \n \n \n Phosphodiesterase 10A (PDE10A) expression was upregulated in calcified arteries from patients and animal models.<\/jats:p>\n <\/jats:list-item>\n \n Genetic deficiency of PDE10A attenuated medial artery calcification and osteogenic transformation of smooth muscle cells.<\/jats:p>\n <\/jats:list-item>\n \n Pharmacological inhibition of PDE10A reduced medial artery calcification in CKD models.<\/jats:p>\n <\/jats:list-item>\n <\/jats:list>\n <\/jats:p>\n <\/jats:sec>\n \n Background<\/jats:title>\n Medial artery calcification is highly prevalent in patients with CKD and peripheral artery disease. It is strongly associated with higher cardiovascular morbidity and mortality. The second messenger cyclic nucleotides cAMP and cyclic guanosine monophosphate play important regulatory roles in a variety of human diseases, which are controlled by distinct phosphodiesterase isozymes. Phosphodiesterases have proven to be highly effective drug targets for the treatment of various conditions. Their function and regulation in medial artery calcification, however, remain unknown.<\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n \n To investigate the role of phosphodiesterase 10A (PDE10A) in medial artery calcification, we used calcified human tibial arteries from patients with peripheral artery disease, calcified arteries from\n in vivo<\/jats:italic>\n models, and calcifying vascular smooth muscle cells\n in vitro<\/jats:italic>\n . Functional studies were conducted using PDE10A knockdown, overexpression, global deletion, and smooth muscle cell\u2013specific deficiency models. Furthermore, we used an\n ex vivo<\/jats:italic>\n aortic ring culture model. The therapeutic potential of the pharmacological PDE10A inhibitor, TAK-063, was evaluated in two distinct\n in vivo<\/jats:italic>\n calcification models: vitamin D\n 3<\/jats:sub>\n injection and the 5\/6 nephrectomy CKD model.\n <\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n We observed that PDE10A was increased in calcifying vascular smooth muscle cells\n in vitro<\/jats:italic>\n , calcified arteries\n in vivo<\/jats:italic>\n , and calcified human tibial arteries. Knockdown and inhibition of PDE10A markedly attenuated phosphate-induced smooth muscle cell osteogenic transformation and calcification, whereas overexpression of PDE10A enhanced smooth muscle cell calcification. Consistently, both global and smooth muscle cell\u2013specific PDE10A deficiency significantly reduced medial artery calcification\n in vivo<\/jats:italic>\n , and deletion of PDE10A alleviated calcification in the aortic ring model. Mechanistically, PDE10A promoted medial artery calcification through activation of the p38 mitogen-activated protein kinase\u2013matrix metalloproteinase-3 signaling axis. In addition, the inhibitor TAK-063 significantly reduced medial artery calcification in both the vitamin D\n 3<\/jats:sub>\n and 5\/6 nephrectomy models.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions<\/jats:title>\n \n PDE10A was a critical mediator of medial artery calcification, and pharmacological inhibition effectively reduced medial artery calcification\n in vivo<\/jats:italic>\n .\n <\/jats:p>\n <\/jats:sec>","DOI":"10.1681\/asn.0000001164","type":"journal-article","created":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T18:00:08Z","timestamp":1781719208000},"update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Smooth Muscle Cell\u2013Specific Expression of Cyclic Nucleotide Phosphodiesterase 10a Promotes the Development of Medial Artery Calcification"],"prefix":"10.1681","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-2459-7055","authenticated-orcid":false,"given":"Ying","family":"Jin","sequence":"first","affiliation":[{"name":"Division of Vascular Surgery and Endovascular Therapy, Department of Surgery, Yale University School of Medicine, New Haven, Connecticut"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-6208-264X","authenticated-orcid":false,"given":"Yangzhouyun","family":"Xie","sequence":"additional","affiliation":[{"name":"Division of Vascular Surgery and Endovascular Therapy, Department of Surgery, Yale University School of Medicine, New Haven, Connecticut"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-7468-873X","authenticated-orcid":false,"given":"Sean","family":"Davis","sequence":"additional","affiliation":[{"name":"Division of Vascular Surgery and Endovascular Therapy, Department of Surgery, Yale University School of Medicine, New Haven, Connecticut"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alyssa M.","family":"Flores","sequence":"additional","affiliation":[{"name":"Division of Vascular and Endovascular Surgery, Department of Surgery, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xue-Lin","family":"Wang","sequence":"additional","affiliation":[{"name":"Division of Vascular and Endovascular Surgery, Department of Surgery, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7567-9930","authenticated-orcid":false,"given":"Raul J.","family":"Guzman","sequence":"additional","affiliation":[{"name":"Division of Vascular Surgery and Endovascular Therapy, Department of Surgery, Yale University School of Medicine, New Haven, Connecticut"},{"name":"Division of Vascular and Endovascular Surgery, Department of Surgery, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0323-6700","authenticated-orcid":false,"given":"Yujun","family":"Cai","sequence":"additional","affiliation":[{"name":"Division of Vascular Surgery and Endovascular Therapy, Department of Surgery, Yale University School of Medicine, New Haven, Connecticut"},{"name":"Division of Vascular and Endovascular Surgery, Department of Surgery, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,6,18]]},"reference":[{"issue":"5","key":"B1-20260810","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.semnephrol.2004.06.003","article-title":"Arterial calcification in chronic kidney disease","volume":"24","author":"Burke","year":"2004","journal-title":"Semin Nephrol."},{"issue":"37","key":"B2-20260810","doi-asserted-by":"crossref","first-page":"5870","DOI":"10.2174\/1381612820666140212210451","article-title":"Mechanisms of medial arterial calcification in diabetes","volume":"20","author":"Chistiakov","year":"2014","journal-title":"Curr Pharm Des."},{"issue":"23","key":"B3-20260810","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1093\/eurheartj\/ehu163","article-title":"Medial vascular calcification revisited: review and perspectives","volume":"35","author":"Lanzer","year":"2014","journal-title":"Eur Heart J."},{"issue":"6","key":"B4-20260810","first-page":"E212","article-title":"Peripheral arterial calcification: prevalence, mechanism, detection, and clinical implications","volume":"83","author":"Rocha-Singh","year":"2014","journal-title":"Catheter Cardiovasc Interv."},{"issue":"2","key":"B5-20260810","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.atherosclerosis.2005.01.024","article-title":"Calcification of elastic fibers in human atherosclerotic plaque","volume":"180","author":"Bobryshev","year":"2005","journal-title":"Atherosclerosis."},{"issue":"1","key":"B6-20260810","doi-asserted-by":"crossref","first-page":"121","DOI":"10.2215\/CJN.01760506","article-title":"Calcification of coronary intima and media: immunohistochemistry, backscatter imaging, and x-ray analysis in renal and nonrenal patients","volume":"2","author":"Gross","year":"2007","journal-title":"Clin J Am Soc Nephrol."},{"issue":"3","key":"B7-20260810","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.carpath.2005.03.002","article-title":"Age-related changes in plaque composition: a study in patients suffering from carotid artery stenosis","volume":"14","author":"van Oostrom","year":"2005","journal-title":"Cardiovasc Pathol."},{"issue":"2","key":"B8-20260810","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1161\/ATVBAHA.114.304764","article-title":"Prevalence of nonatheromatous lesions in peripheral arterial disease","volume":"35","author":"O'Neill","year":"2015","journal-title":"Arterioscler Thromb Vasc Biol."},{"issue":"4","key":"B9-20260810","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1080\/00313020802036764","article-title":"Peripheral vascular disease: who gets it and why? A histomorphological analysis of 261 arterial segments from 58 cases","volume":"40","author":"Soor","year":"2008","journal-title":"Pathology."},{"issue":"5-6","key":"B10-20260810","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1159\/000090182","article-title":"Atherosclerosis and vascular calcification in chronic renal failure","volume":"28","author":"Campean","year":"2005","journal-title":"Kidney Blood Press Res."},{"issue":"4","key":"B11-20260810","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1007\/s10157-005-0385-4","article-title":"Pathogenesis of vascular calcification in dialysis patients","volume":"9","author":"Ketteler","year":"2005","journal-title":"Clin Exp Nephrol."},{"issue":"6","key":"B12-20260810","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1097\/01.mnh.0000168336.67499.c0","article-title":"Arteriosclerosis, vascular calcifications and cardiovascular disease in uremia","volume":"14","author":"London","year":"2005","journal-title":"Curr Opin Nephrol Hypertens."},{"issue":"9","key":"B13-20260810","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1093\/ndt\/gfh303","article-title":"Natural history of vascular calcification in dialysis and transplant patients","volume":"19","author":"Moe","year":"2004","journal-title":"Nephrol Dial Transplant."},{"issue":"2","key":"B14-20260810","doi-asserted-by":"crossref","first-page":"146","DOI":"10.5414\/CNP63146","article-title":"Mechanisms of vascular calcification in renal disease","volume":"63","author":"Shanahan","year":"2005","journal-title":"Clin Nephrol."},{"issue":"2","key":"B15-20260810","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/j.jvs.2017.06.086","article-title":"Association of arterial calcification with chronic limb ischemia in patients with peripheral artery disease","volume":"67","author":"Zettervall","year":"2018","journal-title":"J Vasc Surg."},{"issue":"4","key":"B16-20260810","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1161\/hy1001.096358","article-title":"Arterial calcifications, arterial stiffness, and cardiovascular risk in end-stage renal disease","volume":"38","author":"Blacher","year":"2001","journal-title":"Hypertension."},{"issue":"7","key":"B17-20260810","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1161\/CIRCRESAHA.113.300937","article-title":"MicroRNA in cardiovascular calcification: focus on targets and extracellular vesicle delivery mechanisms","volume":"112","author":"Goettsch","year":"2013","journal-title":"Circ Res."},{"issue":"3","key":"B18-20260810","doi-asserted-by":"crossref","first-page":"2242","DOI":"10.1016\/j.ijcard.2013.01.211","article-title":"Nalp3 inflammasome is activated and required for vascular smooth muscle cell calcification","volume":"168","author":"Wen","year":"2013","journal-title":"Int J Cardiol."},{"issue":"6","key":"B19-20260810","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1038\/ki.2012.482","article-title":"Phosphate-induced autophagy counteracts vascular calcification by reducing matrix vesicle release","volume":"83","author":"Dai","year":"2013","journal-title":"Kidney Int."},{"issue":"9","key":"B20-20260810","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1093\/cvr\/cvab240","article-title":"Cyclic GMP modulating drugs in cardiovascular diseases: mechanism-based network pharmacology","volume":"118","author":"Petraina","year":"2022","journal-title":"Cardiovasc Res."},{"issue":"1","key":"B21-20260810","doi-asserted-by":"crossref","first-page":"4","DOI":"10.3390\/jcdd9010004","article-title":"PDE-mediated cyclic nucleotide compartmentation in vascular smooth muscle cells: from basic to a clinical perspective","volume":"9","author":"Lorigo","year":"2021","journal-title":"J Cardiovasc Dev Dis."},{"key":"B22-20260810","doi-asserted-by":"crossref","first-page":"107278","DOI":"10.1016\/j.vph.2024.107278","article-title":"The perspective of cAMP\/cGMP signaling and cyclic nucleotide phosphodiesterases in aortic aneurysm and dissection","volume":"154","author":"Shu","year":"2024","journal-title":"Vascul Pharmacol."},{"issue":"3","key":"B23-20260810","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1124\/pr.58.3.5","article-title":"Cyclic nucleotide phosphodiesterases: molecular regulation to clinical use","volume":"58","author":"Bender","year":"2006","journal-title":"Pharmacol Rev."},{"issue":"3","key":"B24-20260810","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/0303-7207(82)90135-6","article-title":"Identification and properties of cyclic nucleotide phosphodiesterases","volume":"28","author":"Beavo","year":"1982","journal-title":"Mol Cell Endocrinol."},{"key":"B25-20260810","first-page":"271","article-title":"Calcium-calmodulin-stimulated and cyclic-GMP-specific phosphodiesterases. Tissue distribution, drug sensitivity, and regulation of cyclic GMP levels","volume":"25","author":"Ahn","year":"1992","journal-title":"Adv Second Messenger Phosphoprotein Res."},{"issue":"2","key":"B26-20260810","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/0955-0674(92)90038-E","article-title":"Regulation and function of cyclic nucleotides","volume":"4","author":"Bentley","year":"1992","journal-title":"Curr Opin Cell Biol."},{"issue":"2","key":"B27-20260810","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/S0955-0674(99)00073-3","article-title":"Regulation of cAMP and cGMP signaling: new phosphodiesterases and new functions","volume":"12","author":"Soderling","year":"2000","journal-title":"Curr Opin Cell Biol."},{"issue":"3","key":"B28-20260810","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1161\/01.RES.0000256354.95791.f1","article-title":"Overview of PDEs and their regulation","volume":"100","author":"Omori","year":"2007","journal-title":"Circ Res."},{"issue":"2","key":"B29-20260810","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1124\/jpet.109.155994","article-title":"Phosphodiesterase 10A inhibitor activity in preclinical models of the positive, cognitive, and negative symptoms of schizophrenia","volume":"331","author":"Grauer","year":"2009","journal-title":"J Pharmacol Exp Ther."},{"issue":"28","key":"B30-20260810","doi-asserted-by":"crossref","first-page":"43894","DOI":"10.18632\/oncotarget.9707","article-title":"Whole-exome sequencing to identify somatic mutations in peritoneal metastatic gastric adenocarcinoma: a preliminary study","volume":"7","author":"Liu","year":"2016","journal-title":"Oncotarget."},{"issue":"4","key":"B31-20260810","doi-asserted-by":"crossref","first-page":"e18136","DOI":"10.1371\/journal.pone.0018136","article-title":"Phosphodiesterase 10A upregulation contributes to pulmonary vascular remodeling","volume":"6","author":"Tian","year":"2011","journal-title":"PLoS One."},{"issue":"7","key":"B32-20260810","doi-asserted-by":"crossref","first-page":"796","DOI":"10.15252\/emmm.201506085","article-title":"A novel thermoregulatory role for PDE10A in mouse and human adipocytes","volume":"8","author":"Hankir","year":"2016","journal-title":"EMBO Mol Med."},{"issue":"1","key":"B33-20260810","doi-asserted-by":"crossref","first-page":"300","DOI":"10.2337\/db13-0247","article-title":"Genetic deletion and pharmacological inhibition of phosphodiesterase 10A protects mice from diet-induced obesity and insulin resistance","volume":"63","author":"Nawrocki","year":"2014","journal-title":"Diabetes."},{"issue":"22","key":"B34-20260810","doi-asserted-by":"crossref","first-page":"9627","DOI":"10.1021\/jm5013648","article-title":"Discovery of 1-[2-fluoro-4-(1H-pyrazol-1-yl)phenyl]-5-methoxy-3-(1-phenyl-1H-pyrazol-5-yl)pyri dazin-4(1H)-one (TAK-063), a highly potent, selective, and orally active phosphodiesterase 10A (PDE10A) inhibitor","volume":"57","author":"Kunitomo","year":"2014","journal-title":"J Med Chem."},{"issue":"12","key":"B35-20260810","doi-asserted-by":"crossref","first-page":"2703","DOI":"10.1093\/cvr\/cvab304","article-title":"Role of PDE10A in vascular smooth muscle cell hyperplasia and pathological vascular remodelling","volume":"118","author":"Luo","year":"2022","journal-title":"Cardiovasc Res."},{"key":"B36-20260810","first-page":"7865484","article-title":"Phosphodiesterase 10A is a mediator of osteogenic differentiation and mechanotransduction in bone marrow-derived mesenchymal stromal cells","volume":"2020","author":"Muller-Deubert","year":"2020","journal-title":"Stem Cell Int."},{"issue":"22","key":"B37-20260810","doi-asserted-by":"crossref","first-page":"3480","DOI":"10.1161\/01.CIR.0000148367.08413.E9","article-title":"Elastin degradation and calcification in an abdominal aorta injury model: role of matrix metalloproteinases","volume":"110","author":"Basalyga","year":"2004","journal-title":"Circulation."},{"issue":"2","key":"B38-20260810","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1016\/j.ajpath.2010.10.006","article-title":"Elastin degradation and vascular smooth muscle cell phenotype change precede cell loss and arterial medial calcification in a uremic mouse model of chronic kidney disease","volume":"178","author":"Pai","year":"2011","journal-title":"Am J Pathol."},{"issue":"11","key":"B39-20260810","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1161\/CIRCRESAHA.123.323699","article-title":"Orphan nuclear receptor NR4A3 promotes vascular calcification via histone lactylation","volume":"134","author":"Ma","year":"2024","journal-title":"Circ Res."},{"issue":"6","key":"B40-20260810","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1093\/cvr\/cvae035","article-title":"Smooth muscle cell-specific matrix metalloproteinase 3 deletion reduces osteogenic transformation and medial artery calcification","volume":"120","author":"Xie","year":"2024","journal-title":"Cardiovasc Res."},{"key":"B41-20260810","doi-asserted-by":"crossref","first-page":"16951","DOI":"10.1038\/srep16951","article-title":"Role of P38 MAPK on MMP activity in photothrombotic stroke mice as measured using an ultrafast MMP activatable probe","volume":"5","author":"Chang","year":"2015","journal-title":"Sci Rep."},{"issue":"6","key":"B42-20260810","first-page":"1135","article-title":"Inhibition of the p38 mitogen-activated protein kinase by SB 203580 blocks PMA-induced Mr 92,000 type IV collagenase secretion and in vitro invasion","volume":"58","author":"Simon","year":"1998","journal-title":"Cancer Res."},{"issue":"37","key":"B43-20260810","doi-asserted-by":"crossref","first-page":"39042","DOI":"10.1074\/jbc.M404958200","article-title":"Differential regulation of membrane type 1-matrix metalloproteinase activity by ERK 1\/2- and p38 MAPK-modulated tissue inhibitor of metalloproteinases 2 expression controls transforming growth factor-beta1-induced pericellular collagenolysis","volume":"279","author":"Munshi","year":"2004","journal-title":"J Biol Chem."},{"key":"B44-20260810","doi-asserted-by":"crossref","first-page":"218","DOI":"10.3389\/fncel.2017.00218","article-title":"Upregulation of matrix metalloproteinase-9 in primary cultured rat astrocytes induced by 2-chloroethanol via MAPK signal pathways","volume":"11","author":"Wang","year":"2017","journal-title":"Front Cell Neurosci."},{"issue":"35","key":"B45-20260810","doi-asserted-by":"crossref","first-page":"32360","DOI":"10.1074\/jbc.M204296200","article-title":"Activation of p38 alpha MAPK enhances collagenase-1 (matrix metalloproteinase (MMP)-1) and stromelysin-1 (MMP-3) expression by mRNA stabilization","volume":"277","author":"Reunanen","year":"2002","journal-title":"J Biol Chem."},{"issue":"1","key":"B46-20260810","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.bbrc.2012.11.071","article-title":"p38 MAPK alpha mediates cytokine-induced IL-6 and MMP-3 expression in human cardiac fibroblasts","volume":"430","author":"Sinfield","year":"2013","journal-title":"Biochem Biophys Res Commun."},{"issue":"4","key":"B47-20260810","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1681\/ASN.0000000875","article-title":"High phosphate and low protein mediate arterial and cutaneous vascular calcification in CKD mice","volume":"37","author":"Jin","year":"2026","journal-title":"J Am Soc Nephrol."},{"key":"B48-20260810","doi-asserted-by":"crossref","first-page":"107858","DOI":"10.1016\/j.pharmthera.2021.107858","article-title":"Role of phosphodiesterase 1 in the pathophysiology of diseases and potential therapeutic opportunities","volume":"226","author":"Samidurai","year":"2021","journal-title":"Pharmacol Ther."},{"issue":"7","key":"B49-20260810","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1161\/01.ATV.0000225807.76419.a7","article-title":"Matrix metalloproteinase inhibition attenuates aortic calcification","volume":"26","author":"Qin","year":"2006","journal-title":"Arterioscler Thromb Vasc Biol."},{"issue":"2","key":"B50-20260810","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/S0021-9150(02)00107-7","article-title":"Coronary artery calcification is related to functional polymorphism of matrix metalloproteinase 3: the Helsinki Sudden Death Study","volume":"164","author":"Pollanen","year":"2002","journal-title":"Atherosclerosis."},{"issue":"6","key":"B51-20260810","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1093\/cvr\/cvae064","article-title":"Matrix metalloproteinase-3 joins a growing list of proteases that regulate vascular calcification","volume":"120","author":"Giachelli","year":"2024","journal-title":"Cardiovasc Res."},{"issue":"12","key":"B52-20260810","doi-asserted-by":"crossref","first-page":"2527","DOI":"10.1161\/01.ATV.20.12.2527","article-title":"Mitogen-activated protein kinases mediate matrix metalloproteinase-9 expression in vascular smooth muscle cells","volume":"20","author":"Cho","year":"2000","journal-title":"Arterioscler Thromb Vasc Biol."},{"issue":"1","key":"B53-20260810","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1046\/j.1523-1755.2002.00434.x","article-title":"Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients","volume":"62","author":"Chertow","year":"2002","journal-title":"Kidney Int."},{"issue":"4","key":"B54-20260810","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1093\/ndt\/gfq725","article-title":"The ADVANCE study: a randomized study to evaluate the effects of cinacalcet plus low-dose vitamin D on vascular calcification in patients on hemodialysis","volume":"26","author":"Raggi","year":"2011","journal-title":"Nephrol Dial Transplant."},{"issue":"9","key":"B55-20260810","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1161\/CIRCULATIONAHA.119.044195","article-title":"Slowing progression of cardiovascular calcification with SNF472 in patients on hemodialysis: results of a randomized phase 2b study","volume":"141","author":"Raggi","year":"2020","journal-title":"Circulation."}],"container-title":["Journal of the American Society of Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1681\/ASN.0000001164","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T16:00:41Z","timestamp":1786377641000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1681\/ASN.0000001164"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,18]]},"references-count":55,"URL":"https:\/\/doi.org\/10.1681\/asn.0000001164","relation":{},"ISSN":["1046-6673","1533-3450"],"issn-type":[{"value":"1046-6673","type":"print"},{"value":"1533-3450","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,18]]},"assertion":[{"value":"2026-01-19","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-06-15","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}